MedMira Inc Market Cap ($25.38 Million)
Market Cap & Net Worth: MedMira Inc (MIR)
MedMira Inc market cap. MedMira Inc (V:MIR) has a market capitalization of $25.38 Million (CA$35.09 Million) as of November 1, 2026. Listed on the V stock exchange, this Canada-based company holds position #24183 globally and #895 in its home market, demonstrating a -16.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MedMira Inc's stock price CA$0.05 by its total outstanding shares 701730591 (701.73 Million). Also see MIR cash flow metrics for how efficiently the company converts equity into cash flow.
MedMira Inc Market Cap History (2015–2026)
MedMira Inc market cap history from 2015 to 2026. Data shows change from $22.84 Million to $25.38 Million (-3.00% CAGR). Check MedMira Inc (MIR) stock price for real-time trading data and today's change.
MedMira Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MedMira Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MIR shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
147.74x
MedMira Inc's market cap is 147.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $12.69 Million | $2.26 Million | -$5.16 Million | 5.62x | N/A |
| 2017 | $10.15 Million | $747.34K | -$2.66 Million | 13.58x | N/A |
| 2018 | $5.08 Million | $588.87K | -$2.51 Million | 8.62x | N/A |
| 2019 | $5.08 Million | $527.45K | -$2.11 Million | 9.62x | N/A |
| 2020 | $126.91 Million | $919.07K | -$2.05 Million | 138.08x | N/A |
| 2021 | $101.52 Million | $2.14 Million | -$675.80K | 47.34x | N/A |
| 2022 | $40.61 Million | $952.13K | -$1.83 Million | 42.65x | N/A |
| 2023 | $55.84 Million | $432.53K | -$2.68 Million | 129.10x | N/A |
| 2024 | $48.22 Million | $412.57K | -$3.33 Million | 116.89x | N/A |
| 2025 | $35.53 Million | $240.51K | -$4.52 Million | 147.74x | N/A |
Competitor Companies of MIR by Market Capitalization
Companies near MedMira Inc in the global market cap rankings as of November 1, 2026. Also see total assets of MedMira Inc for a full breakdown of the balance sheet.
Key companies related to MedMira Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of MedMira Inc (2015–2026)
Market capitalization of MedMira Inc from 2015 to today. Between 2015 and today, MedMira Inc's market cap moved from $22.84 Million to $ 25.38 Million, with a yearly change of -3.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$25.38 Million | -28.57% |
| 2025 | CA$35.53 Million | -26.32% |
| 2024 | CA$48.22 Million | -13.64% |
| 2023 | CA$55.84 Million | +37.50% |
| 2022 | CA$40.61 Million | -60.00% |
| 2021 | CA$101.52 Million | -20.00% |
| 2020 | CA$126.91 Million | +2400.00% |
| 2019 | CA$5.08 Million | 0.00% |
| 2018 | CA$5.08 Million | -50.00% |
| 2017 | CA$10.15 Million | -20.00% |
| 2016 | CA$12.69 Million | -44.44% |
| 2015 | CA$22.84 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of MedMira Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.38 Million USD |
| MoneyControl | $25.38 Million USD |
| MarketWatch | $25.38 Million USD |
| marketcap.company | $25.38 Million USD |
| Reuters | $25.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or who… Read more